UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Sentage Holdings Inc.
(Name of Issuer)
Class A ordinary shares, par value $0.005 per share
(Title of Class of Securities)
G8062B114
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ | Rule 13d-1(b) | |
☐ | Rule 13d-1(c) | |
☒ | Rule 13d-1(d) |
* | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. G8062B114 | Page 1 of 6 |
1. |
Names of Reporting Persons
Unit Giant Limited |
2. |
Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ |
3. |
SEC Use Only
|
4. |
Citizenship or Place of Organization
British Virgin Islands |
Number of Shares Beneficially Owned by Each Reporting Person With: |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
1,650,000* | |
7. |
Sole Dispositive Power
0 | |
8. |
Shared Dispositive Power
1,650,000* |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
1,650,000* |
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐
|
11. |
Percent of Class Represented by Amount in Row (9)
58.93%** |
12. |
Type of Reporting Person
FI |
* | Represents ordinary shares held by Unit Giant Limited as of December 31, 2023. |
** | Percentage of class is calculated based on 2,805,325 Class A ordinary shares outstanding as of December 31, 2023, which information was provided by the Issuer to the Reporting Persons on December 31, 2023. |
CUSIP No. G8062B114 | Page 2 of 6 |
1. |
Names of Reporting Persons.
Qiaoling Lu |
2. |
Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐ |
3. |
SEC Use Only
|
4. |
Citizenship or Place of Organization
China |
Number of Shares Beneficially Owned by Each Reporting Person With: |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
1,650,000* | |
7. |
Sole Dispositive Power
0 | |
8. |
Shared Dispositive Power
1,650,000* |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
1,650,000* |
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐
|
11. |
Percent of Class Represented by Amount in Row (9)
58.93%** |
12. |
Type of Reporting Person
IN |
* | Represents ordinary shares indirectly held by Qiaoling Lu through Unit Giant Limited as of December 31, 2023. |
** | Percentage of class is calculated based on 2,805,325 Class A ordinary shares outstanding as of December 31, 2023, which information was provided by the Issuer to the Reporting Persons on December 31, 2023. |
CUSIP No. G8062B114 | Page 3 of 6 |
ITEM 1.
(a) Name of Issuer: Sentage Holdings Inc.
(b) Address of Issuer’s Principal Executive Offices: 501, Platinum Tower 233 Taicang Road, HuangPu, Shanghai City, People’s Republic of China
ITEM 2.
2(a) Name of Person Filing:
Unit Giant Limited
Qiaoling Lu
The shares reported herein are directly held by Unit Giant Limited. Qiaoling Lu is the sole shareholder of Unit Giant Limited. Accordingly, Qiaoling Lu may be deemed to indirectly beneficially own the securities of the Issuer held by Unit Giant Limited.
2(b) Address of Principal Business Office, or if None, Residence:
Address of Unit Giant Limited: Ritter House, Wickhams Cay II, PO Box 3170, Road Town, Tortola, British Virgin Islands
Business address of Qiaoling Lu: 501, Platinum Tower 233 Taicang Road, HuangPu, Shanghai City, People’s Republic of China
2(c) Citizenship:
Unit Giant Limited: British Virgin Islands
Qiaoling Lu: China
2(d) Title of Class of Securities:
Class A ordinary shares, par value $0.005 per share
2(e) CUSIP Number:
G8062B114
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
Not Applicable.
ITEM 4. OWNERSHIP.
The information requested in these paragraphs is incorporated herein by reference to the cover pages to this Schedule 13G.
CUSIP No. G8062B114 | Page 4 of 6 |
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.
ITEM 10. CERTIFICATIONS.
Not applicable.
CUSIP No. G8062B114 | Page 5 of 6 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 13, 2024
By: | /s/ Qiaoling Lu | |
Name: | Qiaoling Lu | |
Unit Giant Limited | ||
By: | /s/ Qiaoling Lu | |
Name: | Qiaoling Lu | |
Title: | Director |
The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
CUSIP No. G8062B114 | Page 6 of 6 |
LIST OF EXHIBITS
Exhibit No. | Description | |
99.1 | Joint Filing Agreement |